Literature DB >> 19095348

Stem cells in melanoma development.

Marianna Sabatino1, David F Stroncek, Harvey Klein, Francesco M Marincola, Ena Wang.   

Abstract

Cutaneous melanoma is a significant health problem worldwide. Available treatments can induce objective tumor regression in a small percent of patients, but these responses are not always associated with improved long-term survival. The resistance of melanoma to therapy and its predestined recurrence are related to the genetic heterogeneity and genomic instability of the tumor. For many years these genetic alterations were thought to be linked to the accumulation of random mutations in functionally differentiated cells which transform them into malignant cells that have lost their ability to differentiate and have acquired drug resistance. In the last few years it has been largely demonstrated that melanoma as other solid tumors contains a subpopulation of cells (CSCs) considered the source of the primary tumor mass, of new tumor nodules and responsible for drug resistance and cancer recurrence. In this review, we provide an overview of findings and advances in CSCs research that are relevant to the initiation, natural history, and the response to treatment of malignant melanoma.

Entities:  

Mesh:

Year:  2008        PMID: 19095348      PMCID: PMC3405359          DOI: 10.1016/j.canlet.2008.10.039

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  63 in total

1.  Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1).

Authors:  A E Greijer; P van der Groep; D Kemming; A Shvarts; G L Semenza; G A Meijer; M A van de Wiel; J A M Belien; P J van Diest; E van der Wall
Journal:  J Pathol       Date:  2005-07       Impact factor: 7.996

2.  Melanoma, a tumor based on a mutant stem cell?

Authors:  James M Grichnik; James A Burch; Ryan D Schulteis; Siqing Shan; Jie Liu; Timothy L Darrow; Carol E Vervaert; Hilliard F Seigler
Journal:  J Invest Dermatol       Date:  2006-01       Impact factor: 8.551

3.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

4.  Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma.

Authors:  Joseph Kwong; Kwok-Wai Lo; Lillian Shuk-Nga Chow; Ka-Fai To; Kwong-Wai Choy; Franky Leung Chan; Samuel C Mok; Dolly P Huang
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

5.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

6.  The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.

Authors:  Volker Lennerz; Martina Fatho; Chiara Gentilini; Roy A Frye; Alexander Lifke; Dorothea Ferel; Catherine Wölfel; Christoph Huber; Thomas Wölfel
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-24       Impact factor: 11.205

7.  ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.

Authors:  Natasha Y Frank; Armen Margaryan; Ying Huang; Tobias Schatton; Ana Maria Waaga-Gasser; Martin Gasser; Mohamed H Sayegh; Wolfgang Sadee; Markus H Frank
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

8.  Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic.

Authors:  Lubna Patrawala; Tammy Calhoun; Robin Schneider-Broussard; Jianjun Zhou; Kent Claypool; Dean G Tang
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

9.  A tumorigenic subpopulation with stem cell properties in melanomas.

Authors:  Dong Fang; Thiennga K Nguyen; Kim Leishear; Rena Finko; Angela N Kulp; Susan Hotz; Patricia A Van Belle; Xiaowei Xu; David E Elder; Meenhard Herlyn
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

10.  Cancer stem cells: an old idea--a paradigm shift.

Authors:  Max S Wicha; Suling Liu; Gabriela Dontu
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

View more
  4 in total

Review 1.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

2.  Characterization of a new human melanoma cell line with CD133 expression.

Authors:  Rosario Gil-Benso; Carlos Monteagudo; Miguel Cerdá-Nicolás; Robert C Callaghan; Sandra Pinto; Alicia Martínez-Romero; Ana Pellín-Carcelén; Teresa San-Miguel; Juan C Cigudosa; Concha López-Ginés
Journal:  Hum Cell       Date:  2012-04-13       Impact factor: 4.174

3.  Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging.

Authors:  Feng Chen; Xiuli Zhang; Kai Ma; Brian Madajewski; Miriam Benezra; Li Zhang; Evan Phillips; Melik Z Turker; Fabio Gallazzi; Oula Penate-Medina; Michael Overholtzer; Mohan Pauliah; Mithat Gonen; Pat Zanzonico; Ulrich Wiesner; Michelle S Bradbury; Thomas P Quinn
Journal:  ACS Appl Mater Interfaces       Date:  2018-01-24       Impact factor: 9.229

4.  Generation of human melanocytes from induced pluripotent stem cells.

Authors:  Shigeki Ohta; Yoichi Imaizumi; Yohei Okada; Wado Akamatsu; Reiko Kuwahara; Manabu Ohyama; Masayuki Amagai; Yumi Matsuzaki; Shinya Yamanaka; Hideyuki Okano; Yutaka Kawakami
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.